[
  {
    "ts": null,
    "headline": "Incyte Announces European Commission Approval of Minjuvi速 (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma",
    "summary": "WILMINGTON, Del., December 17, 2025--Incyte Announces European Commission Approval of Minjuvi速 (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma",
    "url": "https://finnhub.io/api/news?id=91cbfec2626074a9d443915e2045a84c42074418deb94dc115ae1fc7e1692084",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765988400,
      "headline": "Incyte Announces European Commission Approval of Minjuvi速 (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma",
      "id": 137818052,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "WILMINGTON, Del., December 17, 2025--Incyte Announces European Commission Approval of Minjuvi速 (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma",
      "url": "https://finnhub.io/api/news?id=91cbfec2626074a9d443915e2045a84c42074418deb94dc115ae1fc7e1692084"
    }
  }
]